N/A
Manufactured by Fresenius Kabi USA, LLC
27,380 FDA adverse event reports analyzed
Last updated: 2026-04-14
GENTAMICIN SULFATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Fresenius Kabi USA, LLC. The most commonly reported adverse reactions for GENTAMICIN SULFATE include DRUG INEFFECTIVE, ACUTE KIDNEY INJURY, PYREXIA, OFF LABEL USE, RENAL FAILURE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for GENTAMICIN SULFATE.
Out of 15,299 classified reports for GENTAMICIN SULFATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 27,380 FDA FAERS reports that mention GENTAMICIN SULFATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, ACUTE KIDNEY INJURY, PYREXIA, OFF LABEL USE, RENAL FAILURE, DIARRHOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Fresenius Kabi USA, LLC in connection with GENTAMICIN SULFATE. Always verify the specific product and NDC with your pharmacist.